Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Gut Microbiota: A New Path to Treating Syndrome
share announcement

Gut Microbiota: A New Path to Treating Syndrome

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology".

Deadline for manuscript submissions: closed (1 July 2022) | Viewed by 6949

Special Issue Editor

Dr. Lili Li

E-Mail Website
Guest Editor
Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China
Interests: gut microbiota; obesity; metabolic syndrome; metabolism; syndrome; irritable bowel syndrome

Special Issue Information

Dear Colleagues,

“Gut Microbiota: A New Path to Treating Syndromes” is a Special Issue publishing original articles or reviews on all disciplines related to metabolic syndrome and any kinds of syndrome. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention, and public health. The journal should therefore appeal to all professionals with an interest in syndromes and their comorbidities. Article types may include original experiment and reviews, but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. Prevalence studies that compare (research or review) trends across countries or regions or across ethnic groups or relevant subpopulations and provide novel insights and/or conclusions will be considered. The journal also invites reviews presenting original or challenging theories, hypotheses, or alternative interpretations of findings. The journal will contribute to education and inter-professional developments by planning pro and con reviews on current controversies.

The editorial policy is to publish high-quality peer-reviewed manuscripts that provide needed new insight into all aspects of syndrome and its related comorbidities while minimizing the period between submission and publication.

Dr. Lili Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota
  • obesity
  • type 2 diabetes
  • high-fat diet
  • metabolic syndrome
  • irritable bowel syndrome
  • severe acute respiratory syndrome
  • acquired immunodeficiency syndrome
  • syndrome

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 1489 KiB  
Review
The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases
by Codrina-Madalina Palade, Georgiana-Anca Vulpoi, Radu-Alexandru Vulpoi, Vasile Liviu Drug, Oana-Bogdana Barboi and Manuela Ciocoiu
Life 2022, 12(8), 1263; https://doi.org/10.3390/life12081263 - 19 Aug 2022
Cited by 4 | Viewed by 3847
Abstract
Globally, metabolic diseases such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease pose a major public health threat. Many studies have confirmed the causal relationship between risk factors and the etiopathogenesis of these diseases. Despite this, traditional therapeutic management methods [...] Read more.
Globally, metabolic diseases such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease pose a major public health threat. Many studies have confirmed the causal relationship between risk factors and the etiopathogenesis of these diseases. Despite this, traditional therapeutic management methods such as physical education and diet have proven insufficient. Recently, researchers have focused on other potential pathways for explaining the pathophysiological variability of metabolic diseases, such as the involvement of the intestinal microbiota. An understanding of the relationship between the microbiome and metabolic diseases is a first step towards developing future therapeutic strategies. Currently, much attention is given to the use of biotics family members such as prebiotics (lactolose, soy oligosaccharides, galactooligosaccharides, xylooligosaccharides or inulin) and probiotics (genera Lactobacillus, Bifidobacterium, Lactococcus, Streptococcus or Enterococcus). They can be used both separately and together as synbiotics. Due to their direct influence on the composition of the intestinal microbiota, they have shown favorable results in the evolution of metabolic diseases. The expansion of the research area in the biotics family has led to the discovery of new members, like postbiotics. In the age of personalized medicine, their use as therapeutic options is of great interest to our study. Full article
(This article belongs to the Special Issue Gut Microbiota: A New Path to Treating Syndrome)
►▼ Show Figures

Figure 1

17 pages, 1271 KiB  
Review
Feeding Our Microbiota: Stimulation of the Immune/Semiochemical System and the Potential Amelioration of Non-Communicable Diseases
by David Smith, Sohan Jheeta, Hannya V. Fuentes and Miryam Palacios-Pérez
Life 2022, 12(8), 1197; https://doi.org/10.3390/life12081197 - 05 Aug 2022
Cited by 7 | Viewed by 2631
Abstract
Non-communicable diseases are those conditions to which causative infectious agents cannot readily be assigned. It is increasingly likely that at least some of these conditions are due to the breakdown of the previously mutualistic intestinal microbiota under the influence of a polluted, biocide-rich, [...] Read more.
Non-communicable diseases are those conditions to which causative infectious agents cannot readily be assigned. It is increasingly likely that at least some of these conditions are due to the breakdown of the previously mutualistic intestinal microbiota under the influence of a polluted, biocide-rich, environment. Following the mid-20th century African studies of Denis Burkitt, the environmental cause of conditions such as obesity has been ascribed to the absence of sufficient fibre in the modern diet, however in itself that is insufficient to explain the parallel rise of problems with both the immune system and of mental health. Conversely, Burkitt himself noted that the Maasai, a cattle herding people, remained healthy even with their relatively low intake of dietary fibre. Interestingly, however, Burkitt also emphasised that levels of non-communicable disease within a population rose as faecal weight decreased significantly, to about one third of the levels found in healthy populations. Accordingly, a more cogent explanation for all the available facts is that the fully functioning, adequately diverse microbiome, communicating through what has been termed the microbiota–gut–brain axis, helps to control the passage of food through the digestive tract to provide itself with the nutrition it needs. The method of communication is via the production of semiochemicals, interkingdom signalling molecules, potentially including dopamine. In turn, the microbiome aids the immune system of both adult and, most importantly, the neonate. In this article we consider the role of probiotics and prebiotics, including fermented foods and dietary fibre, in the stimulation of the immune system and of semiochemical production in the gut lumen. Finally, we reprise our suggestion of an ingestible sensor, calibrated to the detection of such semiochemicals, to assess both the effectiveness of individual microbiomes and methods of amelioration of the associated non-communicable diseases. Full article
(This article belongs to the Special Issue Gut Microbiota: A New Path to Treating Syndrome)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop